Literature DB >> 22084215

Real-time ophthalmoscopic findings of superselective intraophthalmic artery chemotherapy in a nonhuman primate model.

Matthew W Wilson1, John S Jackson, Blanca X Phillips, Jacquelyn Buchanan, Sharon Frase, Fan Wang, Jena J Steinle, Clinton F Stewart, Timothy D Mandrell, Barrett G Haik, J Scott Williams.   

Abstract

OBJECTIVE: To report real-time ophthalmoscopic findings during superselective intraophthalmic artery chemotherapy (SSIOAC) in a nonhuman primate model.
METHODS: Six adult male Rhesus macaques (Macacca mulatta) were randomly assigned to 1 of 2 treatment cohorts: melphalan (5 mg/30 mL) or carboplatin (30 mg/30 mL). Each animal underwent 3 separate SSIOAC procedures at 3-week intervals. Digital retinal images were obtained during each infusion. Intravenous fluorescein angiography was performed immediately after each procedure.
RESULTS: All SSIOAC procedures were successfully completed. Toxicities were equally distributed between drug cohorts. Systemic toxicities included mild bone marrow suppression in all animals and anorexia in 1. One animal had greater than 50% narrowing of the treated ophthalmic artery after its second infusion. All 18 procedures (100%) resulted in pulsatile optic nerve and choroid blanching, retinal artery narrowing, and retinal edema. Of the 18 procedures, retinal artery sheathing was found during 17 (94%), and retinal artery precipitates were seen in 10 (56%); choroidal hypoperfusion was seen by fluorescein angiogram in 18 (100%).
CONCLUSION: Real-time ophthalmic investigations are useful and, in our nonhuman primate model, indicate prevalent, acute ocular vascular toxicities during SSIOAC. CLINICAL RELEVANCE: Real-time retinal imaging is feasible in a nonhuman primate model of SSIOAC. Application to SSIOAC in children may shed insight into reported vascular toxicities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22084215      PMCID: PMC3527084          DOI: 10.1001/archophthalmol.2011.330

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  23 in total

1.  Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma.

Authors:  Francis L Munier; Maja Beck-Popovic; Aubin Balmer; Marie-Claire Gaillard; Etienne Bovey; Stefano Binaghi
Journal:  Retina       Date:  2011-03       Impact factor: 4.256

2.  The role of pulsatile flow in controlling microvascular retinal endothelial and pericyte cell apoptosis and proliferation.

Authors:  Tony E Walshe; Paul Connell; Lorna Cryan; Gail Ferguson; Colm O'Brien; Paul A Cahill
Journal:  Cardiovasc Res       Date:  2010-10-28       Impact factor: 10.787

3.  Superselective catheterization of the ophthalmic artery for intraarterial chemotherapy for retinoblastoma.

Authors:  Carol L Shields; Aparna Ramasubramanian; Robert Rosenwasser; Jerry A Shields
Journal:  Retina       Date:  2009-09       Impact factor: 4.256

4.  Effect of pH in glucose infusions on development of thrombophlebitis.

Authors:  E W Fonkalsrud; J Murphy; F G Smith
Journal:  J Surg Res       Date:  1968-11       Impact factor: 2.192

5.  A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results.

Authors:  David H Abramson; Ira J Dunkel; Scott E Brodie; Jonathan W Kim; Y Pierre Gobin
Journal:  Ophthalmology       Date:  2008-03-14       Impact factor: 12.079

6.  Spontaneously Resolving Periocular Erythema and Ciliary Madarosis Following Intra-arterial Chemotherapy for Retinoblastoma.

Authors:  Brian Marr; Pierre Y Gobin; Ira J Dunkel; Scott E Brodie; David H Abramson
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 7.  Retinoblastoma: review of current management.

Authors:  Murali Chintagumpala; Patricia Chevez-Barrios; Evelyn A Paysse; Sharon E Plon; Richard Hurwitz
Journal:  Oncologist       Date:  2007-10

Review 8.  High-dose intravenous melphalan: a review.

Authors:  B L Samuels; J D Bitran
Journal:  J Clin Oncol       Date:  1995-07       Impact factor: 44.544

9.  Treatment of retinoblastoma: current status and future perspectives.

Authors:  Carlos Rodriguez-Galindo; Guillermo L Chantada; Barrett G Haik; Matthew W Wilson
Journal:  Curr Treat Options Neurol       Date:  2007-07       Impact factor: 3.598

10.  Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.

Authors:  Stacey L Berg; Jeffery Stone; Jim J Xiao; Kenneth K Chan; Jed Nuchtern; Robert Dauser; Leticia McGuffey; Patrick Thompson; Susan M Blaney
Journal:  Cancer Chemother Pharmacol       Date:  2004-03-23       Impact factor: 3.333

View more
  12 in total

1.  Ocular tumors: Triumphs, challenges and controversies.

Authors:  Ralph C Eagle
Journal:  Saudi J Ophthalmol       Date:  2013-07

2.  Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis.

Authors:  Jena J Steinle; Qiuhua Zhang; Karin Emmons Thompson; Jordan Toutounchian; C Ryan Yates; Carl Soderland; Fan Wang; Clinton F Stewart; Barrett G Haik; J Scott Williams; J Scott Jackson; Timothy D Mandrell; Dianna Johnson; Matthew W Wilson
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-30       Impact factor: 4.799

3.  Validating a nonhuman primate model of super-selective intraophthalmic artery chemotherapy: comparing ophthalmic artery diameters.

Authors:  Lauren C Ditta; Asim F Choudhri; Brian C Tse; Mark M Landers; Barrett G Haik; Jena J Steinle; J Scott Williams; Matthew W Wilson
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-27       Impact factor: 4.799

4.  Fluorescein angiography findings in both eyes of a unilateral retinoblastoma case during intra-arterial chemotherapy with melphalan.

Authors:  Cem Ozgonul; Neeraj Chaudhary; Raymond Hutchinson; Steven M Archer; Hakan Demirci
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

Review 5.  Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy.

Authors:  C L Shields; E M Fulco; J D Arias; C Alarcon; M Pellegrini; P Rishi; S Kaliki; C G Bianciotto; J A Shields
Journal:  Eye (Lond)       Date:  2012-09-21       Impact factor: 3.775

Review 6.  Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.

Authors:  Eleanor M Pritchard; Michael A Dyer; R Kiplin Guy
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

7.  Superselective intraophthalmic artery chemotherapy in a nonhuman primate model: histopathologic findings.

Authors:  Brian C Tse; Jena J Steinle; Dianna Johnson; Barrett G Haik; Matthew W Wilson
Journal:  JAMA Ophthalmol       Date:  2013-07       Impact factor: 7.389

8.  Novel quinic acid derivative KZ-41 prevents retinal endothelial cell apoptosis without inhibiting retinoblastoma cell death through p38 signaling.

Authors:  Qiuhua Zhang; Youde Jiang; Jordan Toutounchian; Matthew W Wilson; Vanessa Morales-Tirado; Duane D Miller; C Ryan Yates; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-03       Impact factor: 4.799

9.  Electroretinogram monitoring of dose-dependent toxicity after ophthalmic artery chemosurgery in retinoblastoma eyes: six year review.

Authors:  Jasmine H Francis; David H Abramson; Y Pierre Gobin; Brian P Marr; Ira J Dunkel; Elyn R Riedel; Scott E Brodie
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

10.  Outcome of retinoblastoma following limited sessions of intra-arterial chemotherapy in iran.

Authors:  Fariba Ghassemi; Hossein Ghanaati; Reza Karkhaneh; Leila Boujabadi; Seied Zia Tabatabaie; Mohammad Taher Rajabi
Journal:  Iran J Radiol       Date:  2014-08-01       Impact factor: 0.212

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.